Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.

Ther Adv Respir Dis · 2018 · PMC6204616 · PMID 30355049

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an encouraging trendno p-value reported

18 – 20 More recently, with a doubled median PFS and an encouraging trend towards an improvement in overall survival (OS), osimertinib recently received United States Food and Drug Administration (US FDA) approval as a front-line treatment based on a multicenter, international, randomized, double-blind, active-controlled trial (FLAURA) which compared upfront osimertinib

also in 355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.